New treatment shows promise against peanut allergy
In
a first, an oral immunotherapy
drug derived from peanut
protein could help build tolerance
and eliminate potentially deadly
reactions in children and adolescents with severe peanut allergies.
The
study showed that controlled ingestion of the medication, called AR101, derived
from peanut protein, could build tolerance as well as reduce severe allergy
symptoms.
"Almost
6 million American children are currently living with a life-threatening food
allergy," said Christina Ciaccio, Associate Professor from the University
of Chicago in the US.
"Every
three minutes a food allergy reaction sends someone to the emergency room,
contributing to the total annual cost of caring for children with food allergy
to nearly $25 billion. Despite this, not a single treatment for food allergy
has been approved by the FDA," she said.
However,
the drug "is not a quick fix, and it doesn't mean people with peanut
allergy will be able to eat peanuts whenever they want", the researchers
stressed, in the paper published in the New England Journal of Medicine. Read
Complete Article
Comments
Post a Comment